Enanta Pharmaceuticals’ (ENTA) “Buy” Rating Reiterated at HC Wainwright

by · The Markets Daily

HC Wainwright reiterated their buy rating on shares of Enanta Pharmaceuticals (NASDAQ:ENTA – Free Report) in a research report released on Wednesday, MarketBeat reports. HC Wainwright currently has a $20.00 target price on the biotechnology company’s stock.

A number of other equities research analysts have also recently commented on ENTA. Wall Street Zen cut shares of Enanta Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday, August 22nd. Weiss Ratings restated a “sell (d-)” rating on shares of Enanta Pharmaceuticals in a report on Friday, July 17th. Five equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Enanta Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus target price of $21.00.

View Our Latest Research Report on ENTA

Enanta Pharmaceuticals Stock Performance

ENTA opened at $11.88 on Wednesday. The business’s fifty day moving average is $13.15 and its two-hundred day moving average is $13.31. The company has a market cap of $345.95 million, a price-to-earnings ratio of -4.93 and a beta of 0.93. Enanta Pharmaceuticals has a one year low of $7.05 and a one year high of $17.15.

Enanta Pharmaceuticals (NASDAQ:ENTA – Get Free Report) last posted its earnings results on Monday, August 10th. The biotechnology company reported ($0.67) earnings per share for the quarter, missing the consensus estimate of ($0.51) by ($0.16). Enanta Pharmaceuticals had a negative net margin of 96.89% and a negative return on equity of 61.84%. The firm had revenue of $14.36 million during the quarter, compared to analyst estimates of $16.76 million. On average, analysts predict that Enanta Pharmaceuticals will post -2.36 EPS for the current fiscal year.

Hedge Funds Weigh In On Enanta Pharmaceuticals

Institutional investors and hedge funds have recently modified their holdings of the company. Jupiter Topco LLC acquired a new position in Enanta Pharmaceuticals in the 2nd quarter valued at $53,252,000. BlackRock Inc. purchased a new position in shares of Enanta Pharmaceuticals during the 2nd quarter worth $47,304,000. ADAR1 Capital Management LLC acquired a new stake in shares of Enanta Pharmaceuticals during the second quarter worth $19,603,000. Spruce Street Capital LP acquired a new stake in shares of Enanta Pharmaceuticals during the second quarter worth $15,873,698. Finally, Hillsdale Investment Management Inc. purchased a new stake in shares of Enanta Pharmaceuticals in the fourth quarter valued at $6,660,000. Hedge funds and other institutional investors own 94.99% of the company’s stock.

Enanta Pharmaceuticals Company Profile

(Get Free Report)

Enanta Pharmaceuticals, Inc is a biotechnology company focused on discovering and developing small-molecule therapies for viral infections and other diseases. The company’s research has primarily centered on antiviral medicines, including treatments for respiratory syncytial virus (RSV), hepatitis B, and other infectious diseases.

Enanta is best known for its role in the development of glecaprevir, a protease inhibitor used with pibrentasvir in AbbVie’s Mavyret (also marketed as Maviret) treatment for chronic hepatitis C virus infection.

Featured Stories